Prostate cancer — all decisions

The Board granted service connection for prostate cancer on a basis other than as pursuant to the PACT Act, including due to exposure to herbicide agents.

The Board granted a total disability rating based on individual unemployability due to the Veteran's service-connected disabilities.

The Board denied the Veteran's claim for an increased initial rating for prostate cancer residuals, finding that a compensable rating was not warranted prior to September 18, 2023.

The Board denied service connection for prostate cancer, finding no reasonable possibility that the Veteran's condition was due to in-service exposure to ionizing radiation.

The Board denied earlier effective dates for the awards of service connection for prostate cancer, erectile dysfunction, and a scar, as well as special monthly compensation based on loss of use of creative organ.

The Board denied service connection for prostate cancer, hypertension, and a gallbladder disability as there is no evidence of current disabilities at any time during or approximate to the pendency of the claims.

The Board granted service connection for residuals of prostate cancer and hypertension, both presumed to be due to in-service herbicide agent exposure.

The Board granted the appeals, restoring service connection for ischemic heart disease, supraventricular arrhythmia, and hypertension, and granting service connection for prostate cancer.

The Board granted a 100 percent disability rating for prostate cancer, rendering the claim for TDIU moot.

The Veteran is entitled to service connection for prostate cancer, lower abdominal surgical scar, and erectile dysfunction from September 24, 2019.

The Board granted an effective date of May 6, 2021 for the grant of service connection for prostate cancer acinar adenocarcinoma based on direct service connection.

The Board denied service connection for prostate cancer as it did not originate in service, within a year of service, and is not otherwise etiologically related to the Veteran's active duty service.

The Board denied service connection for right lower extremity radiculopathy, denied earlier effective dates for prostate cancer residuals and major depressive disorder, denied increased ratings for CKD, tinnitus, and hearing loss, denied a higher rating for depression, and denied an earlier effective date for prostate cancer residuals. The Board granted TDIU and an earlier effective date for chronic kidney disease.

The Board granted service connection for prostate cancer, a condition presumed to be related to in-service exposure to Agent Orange.

The Board granted the restoration of a 100 percent rating for prostate cancer, effective November 1, 2024.

The Board denied the veteran's claims for an initial, compensable disability rating for prostate cancer and service connection for multiple myeloma. The claim for a skin condition of the neck was remanded due to a duty to assist error.

The Board denied an evaluation in excess of 20 percent for residuals of prostate cancer prior to April 18, 2024 and in excess of 60 percent thereafter, as well as a compensable evaluation for an abdominal scar resulting from prostate cancer. The claim for service connection for basal cell carcinoma was remanded.

The Board restored the 60 percent evaluation for prostate cancer residuals, effective December 23, 2020, as the reduction was improper.

The Board granted earlier effective dates for the award of service connection for coronary artery disease, prostate cancer, and erectile dysfunction, but denied earlier effective dates for PTSD with alcohol use disorder and hypertension.

The Board denied service connection for iron deficiency anemia and remanded the claim for a prostate condition, to include prostatitis and prostate cancer.